Frequent discordance between  ERG  gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration‐resistant prostate cancer by Udager, Aaron M. et al.
FrequentDiscordanceBetween ERGGeneRearrangement
and ERGProtein Expression in aRapidAutopsyCohortof
PatientsWith Lethal,Metastatic,Castration-Resistant
ProstateCancer
Aaron M. Udager,1 Yang Shi,2,3 Scott A. Tomlins,1,3,4,5 Ajjai Alva,5,6 Javed Siddiqui,3
Xuhong Cao,3 Kenneth J. Pienta,7 Hui Jiang,2 Arul M. Chinnaiyan,1,3,4,5,8 and Rohit Mehra1,3,5*
1Departmentof Pathology,UniversityofMichiganHealth System, AnnArbor,Michigan
2Departmentof Biostatistics,UniversityofMichigan Schoolof PublicHealth, AnnArbor,Michigan
3MichiganCenter forTranslational Pathology, AnnArbor,Michigan




7The James BuchananBradyUrological Institute,The JohnsHopkinsHospital, Baltimore,Maryland
8HowardHughesMedical Institute, AnnArbor,Michigan
BACKGROUND. ERG rearrangements in localized prostate cancer can be detected with high
sensitivity and specificity by immunohistochemistry (IHC). However, recent data suggest that
ERG IHC may be less sensitive for ERG rearrangements in castration-resistant prostate cancer
(CRPC). Thus, we sought to examine ERG protein expression in a cohort of rapid autopsy
patients with lethal metastatic CRPC (mCRPC).
METHODS. A tissue microarray (TMA) of tumor sites from these patients was evaluated for
ERG, prostate-specific antigen (PSA), and androgen receptor (AR) expression by IHC and
correlated with ERG rearrangement status by fluorescent in situ hybridization (FISH). IHC
was scored as the product of tumor cell staining intensity (0–3) and percentage of cells positive
(0–100) (overall product score range¼ 0–300).
RESULTS. All 16 (100%) ERG rearrangement negative (ERGneg) patients were also negative
for ERG tumor cell expression (i.e., IHC product score¼ 0). Of the 10 ERG rearrangement
positive (ERGpos) patients, two (20%) were completely negative for ERG tumor cell expression,
while eight (80%) had weak ERG expression (median IHC product score¼ 5–110). Of these
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eight ERGpos patients, five (63%) had at least one tumor site without any detectable ERG
expression. For a given ERGpos patient, ERG expression varied both between and within
tumor sites; AR and PSA expression also varied between tumor sites, and there was no
significant correlation between ERG and AR or PSA expression.
CONCLUSIONS. These data reveal frequent discordance between ERG IHC and ERG FISH
in ERGpos patients from this unique cohort of heavily treated lethal mCRPC. Prostate 74:1199–
1208, 2014. # 2014 Wiley Periodicals, Inc.
KEY WORDS: TMPRSS2-ERG; androgen receptor (AR); immunohistochemistry (IHC);
fluorescent in situ hybridization (FISH); rapid autopsy
INTRODUCTION
Recurrent gene fusions involving the ETS family of
transcription factors have been identified in nearly half
of human prostate cancers [1–4]. When they do occur,
these gene fusions are an early, clonal event in the
pathogenesis of prostate cancer [2,4,5], which has
helped illuminate its multifocal nature and subsequent
clonal metastatic dissemination [6,7]. TMPRSS2-ERG
is the most common ETS gene fusion in prostate
cancer, occurring in more than 40% of all localized
and metastatic tumors [8,9]; it is produced by rear-
rangement of chromosome 21, which brings ERG
expression under androgen control via androgen
receptor (AR)-mediated TMPRSS2 transcriptional reg-
ulation. ERG gene rearrangements can be detected
reliably by fluorescent in situ hybridization (FISH) [8],
and in localized prostate cancer, immunohistochemis-
try (IHC) with an anti-ERG antibody has high sensitiv-
ity and specificity for the ERG gene fusion product,
which demonstrates strong nuclear expression in ERG
rearrangement positive (ERGpos) tumor foci [10,11].
Recent literature suggests that ERG IHC, however,
may be comparatively less sensitive for ERG rear-
rangements in castration-resistant prostate cancer
(CRPC) [12,13], as well as prostate cancer with high-
grade neuroendocrine features (i.e., small cell carcino-
ma of the prostate) [14,15].
Rapid (“warm”) autopsies provide invaluable
opportunities for the procurement of primary and
metastatic tissue samples from patients with ad-
vanced, treatment-resistant tumors [16,17]. At the
University of Michigan Health System, we have
performed rapid autopsies on a large cohort of
patients with heavily treated metastatic CRPC
(mCRPC), and samples from these patients’ tumors
have played an essential role in advancing our
understanding of lethal prostate cancer, including
novel mechanisms of androgen signaling dysregula-
tion [9,18–20]. Because TMPRSS2-ERG is androgen-
regulated in ERGpos prostate cancer, ERG protein
expression may not be a faithful reporter of ERG
rearrangement status in advanced, heavily treated
tumors, which often demonstrate a reactivated but
dysfunctional AR signaling axis [20]. Thus, we sought
to examine the spectrum of ERG protein expression
at various tumor sites, as well as the concordance
between ERG IHC and ERG FISH, in a large cohort of
rapid autopsy patients with lethal mCRPC.
MATERIALSANDMETHODS
A tissue microarray (TMA) comprised of rapid
autopsy material from 30 patients with mCRPC has
been previously described [18]; these patients received
multimodal therapy, including a combination of radi-
cal prostatectomy, hormone deprivation (i.e., bilateral
orchiectomy and/or first-generation anti-androgen
therapy), radiation, and/or chemotherapy. Briefly, the
TMA includes samples from all metastatic tumor sites,
as well as primary tumor within the prostate (when
present at the time of autopsy; i.e., no prior radical
prostatectomy), and each tumor site is represented in
triplicate cores. In the current study, ERG, AR, and
prostate-specific antigen (PSA) IHC was performed
using a BenchMark ULTRA automated stainer and the
ultraView Universal DAB Detection Kit (Ventana
Medical Systems, Oro Valley, AZ). The following
primary antibodies were used: ERG (EPR3864; pre-
dilute, Ventana Medical Systems); PSA (polyclonal;
pre-dilute, Ventana Medical Systems); and, AR
(AR441; pre-dilute, Cell Marque, Rocklin, CA). All
available TMA tissue cores were evaluated for ERG,
AR, and PSA protein expression by two study pathol-
ogists (A.M.U. and R.M.), and cores without tumor
were excluded from further analysis. ERG endothelial
cell expression was used as an internal positive control
for ERG IHC. Staining intensity was scored as negative
(0), weak (1), moderate (2), or strong (3), and the
percentage of positive tumor cells was recorded (0–
100). For ERG and AR, only nuclear expression was
scored. For each evaluable core, an IHC product score
(range 0–300) was calculated as the product of the
staining intensity and percentage of positive tumor
cells. For a given patient and tumor site (e.g., lung
from patient #1), if more than one core was evaluable,
the final IHC product score was calculated as the
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average of all evaluated cores. For TMA cores from
ERGpos patients with negative ERG tumor cell expres-
sion and without discernible ERG endothelial cell
expression, whole tissue sections from parent tissue
blocks were evaluated by ERG IHC to confirm positive
ERG endothelial cell expression. Because protein
expression in tissue sections might be subject to a
number of fixation and methodological variables,
particularly for rapid autopsy specimens [21], TMA
ERG tumor cell expression was validated by whole
tissue sections from at least two parent tissue blocks
for each ERGpos patient.
Statistical correlation between ERG, AR, and PSA
tumor cell expression was assessed by calculating the
Pearson correlation coefficients (PCC) and correspond-
ing P-values for all possible IHC pairs (i.e., ERG and
PSA, ERG and AR, and PSA and AR). All statistical
analyses were performed using R (version 3.0.2). Heat
map plots were generated using GENE-E (Broad
Institute, Cambridge, MA).
RESULTS
We previously reported the clinicopathologic char-
acteristics of and the frequency and mechanism of
TMPRSS2-ERG rearrangements in a rapid autopsy
cohort of patients with lethal mCRPC [9,18]. ERG
protein expression, however, has not been systemati-
cally assessed in this cohort; thus, we sought to
evaluate ERG tumor cell expression by IHC using a
tissue microarray (TMA) containing a range of tumor
sites. Using a dual-color, break-apart ERG FISH meth-
od, our previously published data demonstrated that
10 (33%) of the patients in this cohort were positive for
ERG rearrangement (ERGpos), while 20 (67%) were
negative for ERG rearrangement (ERGneg) [9]. Currently,
we evaluated ERG tumor cell expression in these
patients by assigning each TMA core an IHC product
score (range 0–300; see Materials and Methods).
Twenty-six (87%) patients were evaluable for ERG
tumor cell expression by IHC. Consistent with the
high specificity of ERG IHC for the detection of ERG
rearrangements in prostate cancer [10], all 46 tumor
sites from ERGneg patients were negative for ERG
expression (i.e., IHC product score¼ 0) (Fig. 1K).
Twenty-eight tumor sites from ERGpos patients were
scored for ERG expression, and the number of sites
per patient ranged from one to four. Two (20%) of
the ERGpos patients (patients #2 and #22), both with
high-grade neuroendocrine features, were completely
negative for ERG tumor cell expression across all
sites. For the remaining eight ERGpos patients, ERG
tumor cell expression was weak (median site IHC
product score¼ 5–110) (Fig. 1E). Five (63%) of these
patients had at least one tumor site without any
detectable ERG protein expression (Fig. 1H), and the
maximum IHC product score for any site ranged
from 5 to 32. Thus, altogether, seven (70%) of the
ERGpos patients had completely negative or weak
ERG expression at all tumor sites. The remaining
three ERGpos patients demonstrated weak to moder-
ate ERG tumor cell expression at all sites (maximum
IHC product score¼ 100–220) (Fig. 1B).
To further validate our TMA results, ERG IHC was
performed on whole tissue sections from at least two
parent tissue blocks for each ERGpos patient, including
any TMA site with negative ERG tumor cell expression
but without ERG endothelial cell expression (i.e., no
internal positive control); seven [7] cores without an
internal positive internal control were identified, and
all demonstrated retained ERG endothelial cell expres-
sion on the evaluated corresponding parent tissue
sections. Furthermore, whole-section ERG IHC was
concordant with the corresponding TMA results in all
cases except one (patient #1), for which the discordant
results are noteworthy (Fig. 2). The TMA results
for this patient demonstrated weak or negative ERG
tumor cell expression at all four metastatic tumor sites
(liver, lymph node, soft tissue, and pancreas). The
corresponding whole tissue sections, on the other
hand, revealed remarkable intra-site heterogeneity of
ERG tumor cell expression, ranging from negative to
patchy and weak to diffuse and strong (Fig. 2). ERG
endothelial cell expression, on the other hand, was
moderate to strong throughout these sections. Interest-
ingly, for this patient, the areas of TMA core sampling
(as revealed by holes in the tissue sections) were
concentrated in areas of weak ERG tumor cell expres-
sion (data not shown), providing a plausible explana-
tion for the observed discordance between TMA and
whole-section ERG IHC. Also concordant with the
TMA results, two ERGpos patients (#2 and #22) with
high-grade neuroendocrine features were negative for
ERG tumor cell expression in whole tissue sections. A
third ERGpos patient (#24) with high-grade neuroendo-
crine features demonstrated negative whole-section
ERG tumor cell expression at two metastatic tumor
sites (liver and lymph node) but patchy and weak
ERG tumor cell expression at another site (lung)
(Fig. 3); intriguingly, as opposed to the diffuse high-
grade neuroendocrine features in the liver and lymph
node, the metastatic tumor cells in the lung section
exhibited a predominantly poorly differentiated acinar
morphology. Overall, these data demonstrate that, in
the majority of the heavily treated ERGpos mCRPC
patients studied herein, ERG tumor cell expression, as
detected by IHC, is predominantly weak, with consid-
erable inter- and intra-site heterogeneity.
Because ERG protein expression in ERGpos prostate
cancer is regulated by androgen signaling (via AR
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response elements in the TMPRSS2 promoter) [3], one
possible explanation for the predominantly weak and
heterogeneous ERG tumor cell expression observed
in our cohort is dysregulated androgen signaling.
Previously, we reported on the expression of AR, as
well as the androgen-regulated prostate-specific anti-
gen (PSA), in lethal mCRPC patients [18]; by IHC, AR
and PSA demonstrated variable protein expression
both within and between tumor sites. However, in
that prior study, ERG rearrangement status was not
available, and thus, in order to correlate ERG, AR, and
PSA protein expression in ERGpos tumors, we sought
to reassess AR and PSA IHC in an analogous manner to
ERG. For this study, fresh TMA slides were evaluated
Fig. 1. Discordancebetween ERGIHC and ERGFISHin a rapid autopsy cohort of lethalmCRPC. (A,D,G, J) H&E, (B,E,H,K) ERGIHC,
or (C,F,I,L) ERG FISHin (A^I) ERGpos or (J^L) ERGneg patients. In ERGpos patients, ERG tumor cell expression ranges from (B) diffuse and
moderate to (E) patchy and weak to (H) negative, and ERG IHC is negative in ERGneg patients (K). Strong ERG endothelial cell expression
(black arrowheads) provides aninternalpositive control for IHC stainingincaseswithnegativeERGtumorcell expression.Dual-color, break-
apart FISH method to determine ERG rearrangement status: wild type ERG allele¼yellow signal (colocalized signals; yellow arrowhead),
andrearrangedERG allele¼ singlegreensignal (greenarrowhead).H&EandERGIHC¼ 400magnification.
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Fig. 2. Intrasite heterogeneityof ERG tumor cell expression in a case of lethal ERGposmCRPC. (Toppanel) Low-power image of pancreas
involvedbyERGposmCRPC(patient#1)demonstrating significantintrasiteheterogeneityofERGtumorcell expression (ERGIHC;20mag-
nification). Letters correspond to higher power images in bottom panel. (Bottom panel; A and B) High-power images of areas indicated
by letters in the top panel, showing (A) diffuse and strong or (B) patchy and weak ERG tumor cell expression (left sub-panel¼H&E, right
sub-panel¼ ERGIHC;400). StrongERGendothelialcellexpression (blackarrowheads)provides aninternalcontrol for IHCstaininginareas
withweakERGtumorcellexpression.
Fig. 3. Intersite heterogeneity of ERG tumor cell expression in a case of lethal ERGpos mCRPC. (A^C) H&E or (D^F ) ERG IHC
of (A,D) liver, (B, E ) soft tissue, or (C, F ) lung in an ERGpos patient with mCRPC (patient #24).Tumor cells in the liver and soft tissue
(A,B,D,E ) exhibitedhigh-gradeneuroendocrinemorphology andwerenegative for ERGexpression,whereas tumorcells in the lung (C,F )
demonstrated a poorly differentiated acinar morphology and had patchy andweak ERG expression. Strong ERG endothelial cell expression
(black arrowheads) provides an internal control for IHC staining in areaswith negative or weak ERG tumor cell expression. 200magnifica-
tion.InsetinCandF¼1,000magnification.
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for AR and PSA tumor cell expression by IHC using
current staining protocols and available antibodies
(see Materials and Methods). Thirty-two tumor sites
from ERGpos patients were scored for AR expression,
and the number of sites per patient ranged from two
to five. Overall, maximum AR IHC product scores
ranged from 0 to 290 (median¼ 165); five (50%) of the
ERGpos patients had a maximum score greater than
200, while two (20%) had a maximum score less than
100. One (10%) ERGpos patient, with high-grade
neuroendocrine features, was negative for AR expres-
sion at all three tumor sites. Another ERGpos patient,
also with high-grade neuroendocrine features, was
negative for AR expression at three of five tumor sites,
while the remaining two sites exhibited relatively
robust expression (median IHC product score¼ 200).
In all, four (40%) ERGpos patients had at least one
tumor site without AR protein expression, and the
maximum AR IHC product score for any site in these
patients ranged from 0 to 205. Thirty tumor sites from
ERGpos patients were scored for PSA expression, and
the number of sites per patient ranged from two to
four. Overall, maximum PSA IHC product scores
ranged from 0 to 300 (median¼ 130); four (40%) of
the ERGpos patients had a maximum PSA IHC score
greater than 200, while two (20%) had a maximum
score less than 100. One (10%) ERGpos patient, with
high-grade neuroendocrine features, was negative for
PSA expression at all three tumor sites. In all, three
(30%) ERGpos patients had at least one tumor site
without PSA protein expression, and the maximum
PSA IHC product score for any site in these patients
ranged from 0 to 300. Thus, while the majority of
patients with ERGpos mCRPC demonstrated moderate
AR and PSA expression, there was significant variabil-
ity between tissue sites, and a proportion of patients
had at least one negative tumor site.
We next sought to examine possible correlation
between ERG, AR, and PSA IHC in ERGpos and
ERGneg patients in our cohort. For ERGpos patients,
negative, weak, or moderate ERG expression was
observed with corresponding variable AR and PSA
expression (Figs. 4 and 5); in these patients, there was
no significant correlation between ERG and AR or
PSA expression (Fig. 5). Interestingly, while some
tumor sites exhibited negative ERG expression despite
moderate AR expression (Fig. 4G), the opposite pat-
tern was not observed (i.e., no sites with negative AR
expression were positive for ERG expression). Finally,
in ERGneg patients, AR and PSA were strongly and
significantly correlated (PCC¼ 0.76; P-value< 0.01),
and similarly, there was a trend toward significant,
moderate correlation between AR and PSA expression
in ERGpos patients (PCC¼ 0.57; P-value¼ 0.07) (Fig. 5).
Thus, in this cohort of highly treated lethal ERGpos
mCRPC, there were differences in the correlation
between AR and two androgen-regulated gene prod-
ucts (i.e., ERG from TMPRSS2-ERG and PSA).
DISCUSSION
Our data demonstrate profound discordance be-
tween ERG IHC and ERG FISH in ERGpos patients
from a unique cohort of lethal, heavily treated
mCRPC. ERG tumor cell expression is negative or
weak in the vast majority of ERGpos patients, and
when present, there is considerable inter- and intra-
site heterogeneity. In addition, there is no significant
correlation between ERG and AR expression in these
tumors, despite known regulation of TMPRSS2-ERG
by AR responsive promoter elements in clinically
localized prostate cancer [3]. Taken together, these
results suggest dysregulation of androgen signaling in
lethal mCRPC. Intriguingly, recent exomic sequencing
of a subset of this rapid autopsy cohort uncovered
recurrent mutations in genes encoding essential AR
transcriptional cofactors, including FOXA1, MLL2,
UTX/KDM6A, and ASXL1 [20].
Emerging data suggest low-level discordance be-
tween ERG IHC and ERG FISH in a subset (approxi-
mately 10–20%) of patients with metastatic prostate
cancer [12,13]. Our results extend this finding to lethal
mCRPC; however, while the ERG IHC results pre-
sented herein are quite striking, this rapid autopsy
cohort represents a unique, heavily treated group
of lethal mCRPC. Therefore, we believe these data
should be applied cautiously, and additional studies
investigating the effect of current hormone therapy
and chemotherapeutic regimens on ERG protein
expression in ERGpos metastatic prostate cancer are
warranted.
ERG IHC has poor overall concordance with ERG
FISH in localized prostate cancer with high-grade
neuroendocrine features [14,15]. Our TMA and whole
tissue sections results expand this observation to lethal
mCRPC with high-grade neuroendocrine features,
as all three of the ERGpos patients with high-grade
neuroendocrine features in our cohort showed nega-
tive ERG tumor cell expression at the majority of
tumor sites. AR and PSA expression in these tumors
was also mostly negative or weak, although moderate
expression of both proteins was detected at some sites.
Interestingly, while tumor cells for one patient (#24)
demonstrated diffuse high-grade neuroendocrine mor-
phology without ERG expression at multiple sites,
metastatic tumor cells in the lung exhibited a poorly
differentiated acinar morphology and showed patchy
and weak ERG expression (Fig. 3), supporting the idea
that the androgen signaling pathway may be down-
regulated during progression from conventional acinar
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adenocarcinoma to high-grade neuroendocrine pros-
tate cancer [22–26].
Our results suggest some practical implications
from both a diagnostic and therapeutic perspective.
First and foremost, our data confirm the high specificity
of ERG IHC for the detection of ERG gene rearrange-
ments in prostate cancer, as none of the ERGneg
patients showed ERG tumor cell expression at any site.
Thus, the detection of ERG expression in prostate
cancer cells is essentially diagnostic for ERG rearrange-
ment. Second, ERG FISH may be the preferred method
for detecting ERG gene rearrangements in certain
specific instances, such as known metastatic prostate
cancer and high-grade tumors with neuroendocrine
features [27]. It is important to note, of course, that the
utility of either modality (i.e., ERG FISH or ERG IHC)
is limited to cases of prostate cancer with an ERG
rearrangement, and therefore, a negative result does
not exclude a diagnosis of prostate cancer.
Our results may also have important clinical con-
sequences for patients with mCRPC, particularly
in regards to selection of targeted therapeutics in
the emerging era of personalized medicine [27,28].
Because ERG expression is regulated by androgen
signaling in ERGpos prostate cancer, it is clear that ERG
expression (as detected by IHC) is affected by the
androgen signaling status of these cells. Future studies
may be indicated to evaluate ERG protein expression
Fig. 4. Discordance between ERGandARor PSA expression in lethal ERGposmCRPC. (A,D,G) ERGIHC, (B,E,H) AR IHC, or (C,F,I)
PSA IHC in three patients (A^C;D^F; or,G^I) with ERGpos mCRPC. ERG tumor cell expression is (G) negative, (D) patchy and weak,
or (A) diffuse and moderate, and corresponding AR and PSA expression is variable (B, C, E, F, H, I). Strong ERG endothelial cell
expression (black arrowheads) provides an internal control for IHC staining in areas with negative or weak ERG tumor cell expression.
400magnification.
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as a biomarker for response to next-generation anti-
androgen therapies in patients with ERGpos CRPC.
Finally, ERG protein expression in ERGpos CRPC may
also be a biomarker for the selection of patients to
receive targeted ETS rearrangement-based therapies.
PARP1, for example, is required for ERG-mediated
transcription, and the utility of PARP1 inhibitor thera-
py for patients with ERGpos mCRPC is currently being
explored in clinical trials (e.g., NCT01576172) [29].
Presumably, targeted PARP1 therapy is dependent on
ERG protein expression in tumor cells, and therefore,
patients with ERG tumor cell expression (as deter-
mined by IHC in this trial) may benefit from PARP1
inhibitor therapy, while patients without ERG tumor
cell expression may not. Future clinical trials targeting
prostate cancer with ETS gene fusions will need to
consider the potential discordance between ERG rear-
rangement status and ERG protein expression by IHC
prior to selecting testing modalities for the trial.
CONCLUSIONS
In summary, herein we have characterized ERG
protein expression in a unique cohort of rapid autopsy
patients with heavily treated, lethal mCRPC. Further
studies are warranted to delineate the exact mecha-
nisms underlying the profound discordance between
ERG rearrangement and ERG protein expression in
these tumors.
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